APO Research
Talk to an analyst

APO RESEARCH · REPORT

Innovative Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Innovative Drug Market Outlook and Growth Opportunities 2026

23 December 2025217 pages

Choose your research edition.

Industry ResearchInnovative Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Innovative Drug Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Innovative Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Innovative Drug Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Innovative Drug Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Innovative Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Innovative Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Innovative Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Innovative Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Innovative Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Innovative Drug market include Chia Tai Tianqing Pharmaceutical, Teva Pharmaceutical Industries, Sanofi, Johnson & Johnson, Novartis, Novo Nordisk, Roche, Eli Lilly and Company and Shanghai Junshi Biosciences, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Innovative Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Innovative Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Innovative Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Innovative Drug market.

Innovative Drug Segment by Company

Chia Tai Tianqing Pharmaceutical

Teva Pharmaceutical Industries

Sanofi

Johnson & Johnson

Novartis

Novo Nordisk

Roche

Eli Lilly and Company

Shanghai Junshi Biosciences

Pfizer

Hengrui Pharmaceuticals

HUTCHMED

Legend Biotech

Bayer

Bristol-Myers Squibb

BeiGene

Amgen

AbbVie

AstraZeneca

Takeda Pharmaceutical Company

Merck & Co. (MSD)

GlaxoSmithKline (GSK)

Gilead Sciences

Boehringer Ingelheim

Innovative Drug Segment by Type

Biological Medicine

Chemical Medicine

Innovative Drug Segment by Application

Infectious Diseases

Metabolic Diseases

Neurology and Psychiatry

Inflammatory Diseases

Oncology

Others

Innovative Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Innovative Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Innovative Drug key companies, revenue, market share, and recent developments.

3. To split the Innovative Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Innovative Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Innovative Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Innovative Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Innovative Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Innovative Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Innovative Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Innovative Drug industry.

Chapter 3: Detailed analysis of Innovative Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Innovative Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Innovative Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Innovative Drug Industry Trends Table 2. Innovative Drug Industry Drivers Table 3. Innovative Drug Industry Opportunities and Challenges Table 4. Innovative Drug Industry Restraints Table 5. Global Innovative Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Innovative Drug Revenue Share by Company (2021-2026) Table 7. Global Innovative Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Innovative Drug Key Company Manufacturing Base & Headquarters Table 9. Global Innovative Drug Company, Product Type & Application Table 10. Global Innovative Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Innovative Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Biological Medicine Table 15. Significant Companies of Chemical Medicine Table 16. Global Innovative Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Innovative Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Innovative Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Innovative Drug Sales Value Share by Type (2021-2026) Table 20. Global Innovative Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Infectious Diseases Table 22. Significant Companies of Metabolic Diseases Table 23. Significant Companies of Neurology and Psychiatry Table 24. Significant Companies of Inflammatory Diseases Table 25. Significant Companies of Oncology Table 26. Significant Companies of Others Table 27. Global Innovative Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Innovative Drug Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Innovative Drug Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Innovative Drug Sales Value Share by Application (2021-2026) Table 31. Global Innovative Drug Sales Value Share by Application (2027-2032) Table 32. Global Innovative Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Innovative Drug Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Innovative Drug Sales Value Share by Region (2021-2026) Table 35. Global Innovative Drug Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Innovative Drug Sales Value Share by Region (2027-2032) Table 37. Global Innovative Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Innovative Drug Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Innovative Drug Sales Value Market Share by Country (2021-2026) Table 40. Global Innovative Drug Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Innovative Drug Sales Value Market Share by Country (2027-2032) Table 42. Chia Tai Tianqing Pharmaceutical Company Information Table 43. Chia Tai Tianqing Pharmaceutical Business Overview Table 44. Chia Tai Tianqing Pharmaceutical Innovative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Chia Tai Tianqing Pharmaceutical Innovative Drug Product Portfolio Table 46. Chia Tai Tianqing Pharmaceutical Recent Development Table 47. Teva Pharmaceutical Industries Company Information Table 48. Teva Pharmaceutical Industries Business Overview Table 49. Teva Pharmaceutical Industries Innovative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Teva Pharmaceutical Industries Innovative Drug Product Portfolio Table 51. Teva Pharmaceutical Industries Recent Development Table 52. Sanofi Company Information Table 53. Sanofi Business Overview Table 54. Sanofi Innovative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Sanofi Innovative Drug Product Portfolio Table 56. Sanofi Recent Development Table 57. Johnson & Johnson Company Information Table 58. Johnson & Johnson Business Overview Table 59. Johnson & Johnson Innovative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Johnson & Johnson Innovative Drug Product Portfolio Table 61. Johnson & Johnson Recent Development Table 62. Novartis Company Information Table 63. Novartis Business Overview Table 64. Novartis Innovative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Novartis Innovative Drug Product Portfolio Table 66. Novartis Recent Development Table 67. Novo Nordisk Company Information Table 68. Novo Nordisk Business Overview Table 69. Novo Nordisk Innovative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Novo Nordisk Innovative Drug Product Portfolio Table 71. Novo Nordisk Recent Development Table 72. Roche Company Information Table 73. Roche Business Overview Table 74. Roche Innovative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Roche Innovative Drug Product Portfolio Table 76. Roche Recent Development Table 77. Eli Lilly and Company Company Information Table 78. Eli Lilly and Company Business Overview Table 79. Eli Lilly and Company Innovative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Eli Lilly and Company Innovative Drug Product Portfolio Table 81. Eli Lilly and Company Recent Development Table 82. Shanghai Junshi Biosciences Company Information Table 83. Shanghai Junshi Biosciences Business Overview Table 84. Shanghai Junshi Biosciences Innovative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Shanghai Junshi Biosciences Innovative Drug Product Portfolio Table 86. Shanghai Junshi Biosciences Recent Development Table 87. Pfizer Company Information Table 88. Pfizer Business Overview Table 89. Pfizer Innovative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Pfizer Innovative Drug Product Portfolio Table 91. Pfizer Recent Development Table 92. Hengrui Pharmaceuticals Company Information Table 93. Hengrui Pharmaceuticals Business Overview Table 94. Hengrui Pharmaceuticals Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Hengrui Pharmaceuticals Innovative Drug Product Portfolio Table 96. Hengrui Pharmaceuticals Recent Development Table 97. HUTCHMED Company Information Table 98. HUTCHMED Business Overview Table 99. HUTCHMED Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. HUTCHMED Innovative Drug Product Portfolio Table 101. HUTCHMED Recent Development Table 102. Legend Biotech Company Information Table 103. Legend Biotech Business Overview Table 104. Legend Biotech Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Legend Biotech Innovative Drug Product Portfolio Table 106. Legend Biotech Recent Development Table 107. Bayer Company Information Table 108. Bayer Business Overview Table 109. Bayer Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Bayer Innovative Drug Product Portfolio Table 111. Bayer Recent Development Table 112. Bristol-Myers Squibb Company Information Table 113. Bristol-Myers Squibb Business Overview Table 114. Bristol-Myers Squibb Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Bristol-Myers Squibb Innovative Drug Product Portfolio Table 116. Bristol-Myers Squibb Recent Development Table 117. BeiGene Company Information Table 118. BeiGene Business Overview Table 119. BeiGene Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. BeiGene Innovative Drug Product Portfolio Table 121. BeiGene Recent Development Table 122. Amgen Company Information Table 123. Amgen Business Overview Table 124. Amgen Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. Amgen Innovative Drug Product Portfolio Table 126. Amgen Recent Development Table 127. AbbVie Company Information Table 128. AbbVie Business Overview Table 129. AbbVie Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. AbbVie Innovative Drug Product Portfolio Table 131. AbbVie Recent Development Table 132. AstraZeneca Company Information Table 133. AstraZeneca Business Overview Table 134. AstraZeneca Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. AstraZeneca Innovative Drug Product Portfolio Table 136. AstraZeneca Recent Development Table 137. Takeda Pharmaceutical Company Company Information Table 138. Takeda Pharmaceutical Company Business Overview Table 139. Takeda Pharmaceutical Company Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 140. Takeda Pharmaceutical Company Innovative Drug Product Portfolio Table 141. Takeda Pharmaceutical Company Recent Development Table 142. Merck & Co. (MSD) Company Information Table 143. Merck & Co. (MSD) Business Overview Table 144. Merck & Co. (MSD) Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 145. Merck & Co. (MSD) Innovative Drug Product Portfolio Table 146. Merck & Co. (MSD) Recent Development Table 147. GlaxoSmithKline (GSK) Company Information Table 148. GlaxoSmithKline (GSK) Business Overview Table 149. GlaxoSmithKline (GSK) Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 150. GlaxoSmithKline (GSK) Innovative Drug Product Portfolio Table 151. GlaxoSmithKline (GSK) Recent Development Table 152. Gilead Sciences Company Information Table 153. Gilead Sciences Business Overview Table 154. Gilead Sciences Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 155. Gilead Sciences Innovative Drug Product Portfolio Table 156. Gilead Sciences Recent Development Table 157. Boehringer Ingelheim Company Information Table 158. Boehringer Ingelheim Business Overview Table 159. Boehringer Ingelheim Innovative Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 160. Boehringer Ingelheim Innovative Drug Product Portfolio Table 161. Boehringer Ingelheim Recent Development Table 162. Research Programs/Design for This Report Table 163. Authors List of This Report Table 164. Secondary Sources Table 165. Primary Sources List of Figures Figure 1. Innovative Drug Product Image Figure 2. Global Innovative Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Innovative Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Innovative Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Biological Medicine Image Figure 8. Chemical Medicine Image Figure 9. Global Innovative Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Innovative Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Innovative Drug Sales Value Share by Type (2021-2032) Figure 12. Infectious Diseases Image Figure 13. Metabolic Diseases Image Figure 14. Neurology and Psychiatry Image Figure 15. Inflammatory Diseases Image Figure 16. Oncology Image Figure 17. Others Image Figure 18. Global Innovative Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Innovative Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Innovative Drug Sales Value Share by Application (2021-2032) Figure 21. Global Innovative Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Innovative Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Innovative Drug Sales Value (2021-2032) & (US$ Million) Figure 24. North America Innovative Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Innovative Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Innovative Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Innovative Drug Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Innovative Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Innovative Drug Sales Value (2021-2032) & (US$ Million) Figure 30. South America Innovative Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Innovative Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Innovative Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Innovative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Innovative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Innovative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Biological Medicine
  • Chemical Medicine
Applications
  • Infectious Diseases
  • Metabolic Diseases
  • Neurology and Psychiatry
  • Inflammatory Diseases
  • Oncology
  • Others
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Teva Pharmaceutical Industries
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Novo Nordisk
  • Roche
  • Eli Lilly and Company
  • Shanghai Junshi Biosciences
  • Pfizer
  • Hengrui Pharmaceuticals
  • HUTCHMED
  • Legend Biotech
  • Bayer
  • Bristol-Myers Squibb
  • BeiGene
  • Amgen
  • AbbVie
  • AstraZeneca
  • Takeda Pharmaceutical Company
  • Merck & Co. (MSD)
  • GlaxoSmithKline (GSK)
  • Gilead Sciences
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Innovative Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Innovative Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Innovative Drug Market Dynamics
  1. 2.1 Innovative Drug Industry Trends
  2. 2.2 Innovative Drug Industry Drivers
  3. 2.3 Innovative Drug Industry Opportunities and Challenges
  4. 2.4 Innovative Drug Industry Restraints
3 Innovative Drug Market by Company
  1. 3.1 Global Innovative Drug Company Revenue Ranking in 2025
  2. 3.2 Global Innovative Drug Revenue by Company (2021-2026)
  3. 3.3 Global Innovative Drug Company Ranking (2024-2026)
  4. 3.4 Global Innovative Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Innovative Drug Company Product Type and Application
  6. 3.6 Global Innovative Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Innovative Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Innovative Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Innovative Drug Market by Type
  1. 4.1 Innovative Drug Type Introduction
  2. 4.1.1 Biological Medicine
  3. 4.1.2 Chemical Medicine
  4. 4.2 Global Innovative Drug Sales Value by Type
  5. 4.2.1 Global Innovative Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Innovative Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Innovative Drug Sales Value Share by Type (2021-2032)
5 Innovative Drug Market by Application
  1. 5.1 Innovative Drug Application Introduction
  2. 5.1.1 Infectious Diseases
  3. 5.1.2 Metabolic Diseases
  4. 5.1.3 Neurology and Psychiatry
  5. 5.1.4 Inflammatory Diseases
  6. 5.1.5 Oncology
  7. 5.1.6 Others
  8. 5.2 Global Innovative Drug Sales Value by Application
  9. 5.2.1 Global Innovative Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Innovative Drug Sales Value by Application (2021-2032)
  11. 5.2.3 Global Innovative Drug Sales Value Share by Application (2021-2032)
6 Innovative Drug Regional Value Analysis
  1. 6.1 Global Innovative Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Innovative Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Innovative Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Innovative Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Innovative Drug Sales Value (2021-2032)
  7. 6.3.2 North America Innovative Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Innovative Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Innovative Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Innovative Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Innovative Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Innovative Drug Sales Value (2021-2032)
  16. 6.6.2 South America Innovative Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Innovative Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Innovative Drug Sales Value Share by Country, 2025 VS 2032
7 Innovative Drug Country-level Value Analysis
  1. 7.1 Global Innovative Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Innovative Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Innovative Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Innovative Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Innovative Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Innovative Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Innovative Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Innovative Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Innovative Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Innovative Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Innovative Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Innovative Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Innovative Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Innovative Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Innovative Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Innovative Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Innovative Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Innovative Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Innovative Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Innovative Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Innovative Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Innovative Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Innovative Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Innovative Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Innovative Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Innovative Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Innovative Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Innovative Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Innovative Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Innovative Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Innovative Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Innovative Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Innovative Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Innovative Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Innovative Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Innovative Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Innovative Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Innovative Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Innovative Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Innovative Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Innovative Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Innovative Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Innovative Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Innovative Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Innovative Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Innovative Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Innovative Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Innovative Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Innovative Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Innovative Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Innovative Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Innovative Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Innovative Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Innovative Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Innovative Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Innovative Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Innovative Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Innovative Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Innovative Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Innovative Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Innovative Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Innovative Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Innovative Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Innovative Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Innovative Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Innovative Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Innovative Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Innovative Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Innovative Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Innovative Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Innovative Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Innovative Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Innovative Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Innovative Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Innovative Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Innovative Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Innovative Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Innovative Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Innovative Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Innovative Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Innovative Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Innovative Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Innovative Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Innovative Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Innovative Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Innovative Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Innovative Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Innovative Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical Innovative Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical Innovative Drug Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Teva Pharmaceutical Industries
  8. 8.2.1 Teva Pharmaceutical Industries Company Information
  9. 8.2.2 Teva Pharmaceutical Industries Business Overview
  10. 8.2.3 Teva Pharmaceutical Industries Innovative Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Industries Innovative Drug Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Industries Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Innovative Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Innovative Drug Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Innovative Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Innovative Drug Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Innovative Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Innovative Drug Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Novo Nordisk
  32. 8.6.1 Novo Nordisk Company Information
  33. 8.6.2 Novo Nordisk Business Overview
  34. 8.6.3 Novo Nordisk Innovative Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novo Nordisk Innovative Drug Product Portfolio
  36. 8.6.5 Novo Nordisk Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Innovative Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Innovative Drug Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Eli Lilly and Company
  44. 8.8.1 Eli Lilly and Company Company Information
  45. 8.8.2 Eli Lilly and Company Business Overview
  46. 8.8.3 Eli Lilly and Company Innovative Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly and Company Innovative Drug Product Portfolio
  48. 8.8.5 Eli Lilly and Company Recent Developments
  49. 8.9 Shanghai Junshi Biosciences
  50. 8.9.1 Shanghai Junshi Biosciences Company Information
  51. 8.9.2 Shanghai Junshi Biosciences Business Overview
  52. 8.9.3 Shanghai Junshi Biosciences Innovative Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shanghai Junshi Biosciences Innovative Drug Product Portfolio
  54. 8.9.5 Shanghai Junshi Biosciences Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Innovative Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Innovative Drug Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Hengrui Pharmaceuticals
  62. 8.11.1 Hengrui Pharmaceuticals Company Information
  63. 8.11.2 Hengrui Pharmaceuticals Business Overview
  64. 8.11.3 Hengrui Pharmaceuticals Innovative Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hengrui Pharmaceuticals Innovative Drug Product Portfolio
  66. 8.11.5 Hengrui Pharmaceuticals Recent Developments
  67. 8.12 HUTCHMED
  68. 8.12.1 HUTCHMED Company Information
  69. 8.12.2 HUTCHMED Business Overview
  70. 8.12.3 HUTCHMED Innovative Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 HUTCHMED Innovative Drug Product Portfolio
  72. 8.12.5 HUTCHMED Recent Developments
  73. 8.13 Legend Biotech
  74. 8.13.1 Legend Biotech Company Information
  75. 8.13.2 Legend Biotech Business Overview
  76. 8.13.3 Legend Biotech Innovative Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Legend Biotech Innovative Drug Product Portfolio
  78. 8.13.5 Legend Biotech Recent Developments
  79. 8.14 Bayer
  80. 8.14.1 Bayer Company Information
  81. 8.14.2 Bayer Business Overview
  82. 8.14.3 Bayer Innovative Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bayer Innovative Drug Product Portfolio
  84. 8.14.5 Bayer Recent Developments
  85. 8.15 Bristol-Myers Squibb
  86. 8.15.1 Bristol-Myers Squibb Company Information
  87. 8.15.2 Bristol-Myers Squibb Business Overview
  88. 8.15.3 Bristol-Myers Squibb Innovative Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bristol-Myers Squibb Innovative Drug Product Portfolio
  90. 8.15.5 Bristol-Myers Squibb Recent Developments
  91. 8.16 BeiGene
  92. 8.16.1 BeiGene Company Information
  93. 8.16.2 BeiGene Business Overview
  94. 8.16.3 BeiGene Innovative Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BeiGene Innovative Drug Product Portfolio
  96. 8.16.5 BeiGene Recent Developments
  97. 8.17 Amgen
  98. 8.17.1 Amgen Company Information
  99. 8.17.2 Amgen Business Overview
  100. 8.17.3 Amgen Innovative Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Amgen Innovative Drug Product Portfolio
  102. 8.17.5 Amgen Recent Developments
  103. 8.18 AbbVie
  104. 8.18.1 AbbVie Company Information
  105. 8.18.2 AbbVie Business Overview
  106. 8.18.3 AbbVie Innovative Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 AbbVie Innovative Drug Product Portfolio
  108. 8.18.5 AbbVie Recent Developments
  109. 8.19 AstraZeneca
  110. 8.19.1 AstraZeneca Company Information
  111. 8.19.2 AstraZeneca Business Overview
  112. 8.19.3 AstraZeneca Innovative Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 AstraZeneca Innovative Drug Product Portfolio
  114. 8.19.5 AstraZeneca Recent Developments
  115. 8.20 Takeda Pharmaceutical Company
  116. 8.20.1 Takeda Pharmaceutical Company Company Information
  117. 8.20.2 Takeda Pharmaceutical Company Business Overview
  118. 8.20.3 Takeda Pharmaceutical Company Innovative Drug Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Takeda Pharmaceutical Company Innovative Drug Product Portfolio
  120. 8.20.5 Takeda Pharmaceutical Company Recent Developments
  121. 8.21 Merck & Co. (MSD)
  122. 8.21.1 Merck & Co. (MSD) Company Information
  123. 8.21.2 Merck & Co. (MSD) Business Overview
  124. 8.21.3 Merck & Co. (MSD) Innovative Drug Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Merck & Co. (MSD) Innovative Drug Product Portfolio
  126. 8.21.5 Merck & Co. (MSD) Recent Developments
  127. 8.22 GlaxoSmithKline (GSK)
  128. 8.22.1 GlaxoSmithKline (GSK) Company Information
  129. 8.22.2 GlaxoSmithKline (GSK) Business Overview
  130. 8.22.3 GlaxoSmithKline (GSK) Innovative Drug Revenue and Gross Margin (2021-2026)
  131. 8.22.4 GlaxoSmithKline (GSK) Innovative Drug Product Portfolio
  132. 8.22.5 GlaxoSmithKline (GSK) Recent Developments
  133. 8.23 Gilead Sciences
  134. 8.23.1 Gilead Sciences Company Information
  135. 8.23.2 Gilead Sciences Business Overview
  136. 8.23.3 Gilead Sciences Innovative Drug Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Gilead Sciences Innovative Drug Product Portfolio
  138. 8.23.5 Gilead Sciences Recent Developments
  139. 8.24 Boehringer Ingelheim
  140. 8.24.1 Boehringer Ingelheim Company Information
  141. 8.24.2 Boehringer Ingelheim Business Overview
  142. 8.24.3 Boehringer Ingelheim Innovative Drug Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Boehringer Ingelheim Innovative Drug Product Portfolio
  144. 8.24.5 Boehringer Ingelheim Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst